title: Mycosis fungoides-type cutaneous T-cell lymphoma and neutrophilic dermatosis.
abstract: BACKGROUND
  Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL). Patients with limited patch and/or plaque disease have a normal life expectancy. Neutrophilic dermatosis (ND) may be associated with various hematologic disorders. However, its association with CTCL is exceptional and has been reported only twice with leukemic forms of CTCL.
  
  
  METHODS
  Three patients with MF developed ND resistant to conventional therapies and responsible for an impaired quality of life due to constitutional symptoms and painful cutaneous lesions. All patients underwent an aggressive treatment course despite their varying initial clinical stages of MF, and all experienced a fatal outcome less than 18 months after the onset of ND.
  
  
  CONCLUSIONS
  The association of MF with ND is exceptional and carries a poor prognosis, but the pathophysiologic nature of this association remains unclear. It may involve neutrophil chemoattractant cytokine production by tumor cells. A triggering role of interferon alfa is also possible.
authors.affiliation: Department of Dermatology, Hopital Tarnier-Cochin, Paris, France. nathalie.franck@cch.ap-hop-paris.fr
authors.forename: Nathalie
authors.initials: N
authors.lastname: Franck
authors.forename: Agnes
authors.initials: A
authors.lastname: Carlotti
authors.forename: Isabelle
authors.initials: I
authors.lastname: Gorin
authors.forename: Marc
authors.initials: M
authors.lastname: Buffet
authors.forename: Christine
authors.initials: C
authors.lastname: Mateus
authors.forename: Nicolas
authors.initials: N
authors.lastname: Dupin
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D007150:Immunohistochemistry; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016410:Lymphoma, T-Cell, Cutaneous; D008297:Male; D008875:Middle Aged; D009182:Mycosis Fungoides / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D009367:Neoplasm Staging; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D016463:Sweet Syndrome / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents